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β-SpectrinStrategies to prevent diabetic microvascular angiopathy focus on the vascular endothelium. Because red blood
cells (RBCs) are less deformable in diabetes,we explored an original concept linking decreased RBC deformability
to RBC ascorbate and hyperglycemia. We characterized ascorbate concentrations from human and mouse RBCs
and plasma, and showed an inverse relationship between RBC ascorbate concentrations and deformability,
measured by osmotic fragility. RBCs from ascorbate deﬁcient mice were osmotically sensitive, appeared as
spherocytes, and had decreased β-spectrin. These aberrancies reversed with ascorbate repletion in vivo. Under
physiologic conditions, only ascorbate's oxidation product dehydroascorbic acid (DHA), a substrate for facilitated
glucose transporters, was transported into mouse and human RBCs, with immediate intracellular reduction to
ascorbate. In vitro, glucose inhibited entry of physiologic concentrations of dehydroascorbic acid into mouse
and human RBCs. In vivo, plasma glucose concentrations in normal and diabeticmice and humanswere inversely
related to respective RBC ascorbate concentrations, as was osmotic fragility. Human RBC β-spectrin declined as
diabetes worsened. Taken together, hyperglycemia in diabetes produced lower RBC ascorbate with increased
RBC rigidity, a candidate to drive microvascular angiopathy. Because glucose transporter expression, DHA trans-
port, and its inhibition by glucose differed for mouse versus human RBCs, human experimentation is indicated.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Diabetes type 2 is an epidemic public health problem. Poorly con-
trolled diabetes results in acceleratedmicrovascular disease and chronic
debilitating morbidities and mortality (Beckman et al., 2002). Diabetic
microvascular angiopathy is the leading cause of blindness, end stage
renal disease and amputations worldwide, as well as myocardial infarc-
tion, stroke and peripheral arterial disease.
Preventing or delaying microvascular disease could improve the lives
of millions, prevent catastrophic illness, and save billions of dollars. The
pathogenesis of microangiopathy in diabetes is unknown. Clinical efforts
are based on glycemic control. The research focus of some prevention ef-
forts is the endothelium and its role in protecting blood vessels (Fioretto
et al., 2010; Wong et al., 2010). Vascular smooth muscle abnormalities,
platelet dysfunction, abnormal coagulation and impaired vascular repairic acid; GLUT, facilitated glucose
mouse unable to synthesize
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ss article under the CC BY license (htare other pathologies proposed to lead to diabetic vasculopathy (Beckman
et al., 2002; Cubbon et al., 2013). Oxidants generated by hyperglycemia
within endothelial cells (Nishikawa et al., 2000) or other vascular cells
may initiate endothelial cell damage (Yu et al., 2006; Wang et al., 2012).
Endothelial cell damage secondary to hyperglycemia can be one
initiator of diabetic microangiopathy by impairing oxygen delivery,
resulting in microvascular hypoxia. Another plausible pathway is that
oxidants generated by hyperglycemia, from endothelial cells or others,
impair oxygen delivery by affecting the delivery system itself: red
blood cells (RBCs). In fact, substantial evidence indicates that diabetes
induces changes in RBC structure and function through a progressive
decline in RBC deformability (Peterson et al., 1977; McMillan et al.,
1978; Kamada et al., 1992; Virtue et al., 2004; Diamantopoulos et al.,
2004; Brown et al., 2005; Shin et al., 2007; Kung et al., 2009; Keymel
et al., 2011; Buys et al., 2013). RBC deformability is vital to RBC function,
and plays a major role in microvascular ﬂow. Impaired deformability
adversely affects capillary perfusion (Simchon et al., 1987;
Parthasarathi and Lipowsky, 1999). Consistent with decreased
deformability, diabetes is associated with increased RBC fragility and
decreased RBC survival (Peterson et al., 1977; Parthasarathi and
Lipowsky, 1999; Virtue et al., 2004; Kung et al., 2009). Because stiffer
RBCs may compromise the microcirculation and oxygen delivery,tp://creativecommons.org/licenses/by/4.0/).
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hypoxia, with direct clinical implications.
In this regard, there are underappreciated links between RBCs,
vitamin C, and diabetes. Multiple reports describe lower vitamin C
concentrations in diabetic subjects, especially those with microvas-
cular complications such as retinopathy and nephropathy (Som
et al., 1981; Ali and Chakraborty, 1989; Sinclair et al., 1991; Will
and Byers, 1996; Lindsay et al., 1998; Cunningham, 1998; Chen
et al., 2006). However, many datasets utilized unreliable vitamin C
assays, making it difﬁcult to interpret ﬁndings (Will and Byers,
1996; Padayatty et al., 2003). Diabetic vascular disease and vitamin
C deﬁciency were tied together in an early hypothesis (Mann and
Newton, 1975), but it lacked mechanism and supportive evidence.
Consistent with a hypothesized role for a RBC deformability defect
in diabetes, anemia and hemolysis are manifestations of vitamin C
deﬁciency in humans, and in mice (Gulo−/−) unable to synthesize
the vitamin (Chazan and Mistilis, 1963; Hart et al., 1964; Cox,
1968; Maeda et al., 2000). Unfortunately, deformability measures
were not described in vitamin C deﬁcient patients, and their clinical
data are confounded by co-existent vitamin deﬁciencies.
Here we couple original links between diabetes and vitamin C with
RBCs as a key cell type; oxidized vitamin C (dehydroascorbic acid, DHA)
as a key transported substrate; and the chemical structure similarity be-
tween DHA and glucose (Vera et al., 1993; Rumsey et al., 1997; Corpe
et al., 2013). For nearly all tissues, ascorbate transport is mediated by
sodium-dependent vitamin C transporter SVCT2 (Sotiriou et al., 2002).
However, SVCT2 is absent fromRBCs (Mayet al., 2007). Because RBCs con-
tain ascorbate (Li et al., 2012), another transport mechanism exists. It is
likely that the product of ascorbate oxidation, dehydroascorbic acid, is
transported on facilitated glucose transporters (GLUTs) and immediately
reduced to ascorbate within RBCs (Hughes and Maton, 1968; Bianchi
and Rose, 1986; Mendiratta et al., 1998). Based on expressed transporter
data, hyperglycemia from diabetes could inhibit dehydroascorbic acid
entry into RBCs (Vera et al., 1993; Rumsey et al., 1997). Some data do
not support this rationale, but experiments were performed using DHA
concentrations 2–3 orders of magnitude above physiological concentra-
tions, and indirect assays that did not account for substrate degradation
(Montel-Hagen et al., 2008a; Sage andCarruthers, 2014). LowerDHAcon-
centrations could not be investigated due to assay limitations, also pre-
cluding accurate RBC ascorbate measurements (May et al., 2001;
Montel-Hagen et al., 2008a; Li et al., 2012).
Utilizing a recently developed ultrasensitive assay for vitamin C in
RBCs and physiologic transport conditions (Li et al., 2012), we propose
an original multicomponent hypothesis linking vitamin C to diabetes.
The parts of the hypothesis investigated here arewhether low ascorbate
concentrations occur in RBCs in comparison with other cells; whether
low ascorbate concentrations in RBCs have a consequence; andwhether
and how low ascorbate RBC concentrations can be coupled to hypergly-
cemia in vitro and in vivo.
2. Methods
2.1. Materials
Ascorbic acid was purchased from Sigma/Aldrich. Dehydroascorbic
acid was synthesized de novo from ascorbate immediately before each
experiment (Li et al., 2012; Corpe et al., 2013). Antibodies were obtained
from Abcam (Cambridge MA), Santa Cruz Biotechnology (Dallas TX),
and Novus Biologicals (Littleton, CO). Antibodies from Abcam: anti-
GLUT 1 antibody (ab652), anti-GLUT 2 antibody(ab54460), anti-GLUT
3 antibody (ab41525), anti-GLUT 4 antibody (ab654), anti- β actin anti-
body (ab6276), anti- β 1 spectrin (ab2808), and anti-(α+ β) spectrin
(ab11182). Antibodies from Santa Cruz Biotechnology: anti-Ankyrin-1
(sc-12,733). Antibodies from Novus Biologicals: anti-protein 4.2
(NBP1-56,647). All other chemicals were highest purity grade available
commercially.2.2. Mice and Blood Samples from Mice
Animal experiments were approved by the Animal Care and Use
Committee NIDDK, NIH, and were conducted in accordance with NIH
guidelines. Unless otherwise indicated, mice were 10–14 week old
males with free access to food and water, and were maintained on
regular chow diet (NIH-07) without detectable ascorbate (detection
limit 10 nM). Mice were type C57BL/6 (wildtype, WT) (Charles River
Laboratories, Wilmington, MA, USA); transgenic AZIP mice (original
FVB/N A-ZIP/F-1 line) Moitra et al., 1998); and gulonolactone oxidase
(Gulo+/−) mice (Mutant Mouse Regional Resource Center, University
of California at Davis, USA), bred as described (Maeda et al., 2000).
Plasma and RBCs were obtained from mouse whole blood as described
(Li et al., 2012), with the modiﬁcation that samples were centrifuged
at 200 x g for 5 min due to hemolysis (see Fig. 1 and results). When
ascorbate was provided, mice received it via drinking water, which
was changed daily, or via gavage where indicated. See supplementary
methods for additional details.
2.3. Human Subjects and Samples
Clinical research was approved by the Institutional Review Board,
NIDDK/NIAMS, NIH, and conducted in accordance with NIH guidelines.
Blood and cell samples from healthy subjects (NIH Protocols 04-DK-
0021; 99-CC-0168; and 92-DK-0033) and diabetic subjects (NIH
Protocol 04-DK-0021) were obtained and processed as described
(Levine et al., 1996) (Li et al., 2012).
2.4. Erythrocyte Osmotic Fragility
RBC deformability is related to RBC osmotic fragility (Clark et al.,
1983). RBC osmotic fragility based on resistance of RBCs to lysis as a
function of decreasing NaCl concentration was performed as described
(Parpart et al., 1947) with modiﬁcations (see supplementary methods).
2.5. Dehydroascorbic Acid and Ascorbate Transport
2.5.1. Preparation of RBCs
RBCs were prepared as described (Li et al., 2012), with centrifuga-
tion modiﬁcations above.
2.5.2. Transport of Dehydroascorbic Acid and Ascorbate into Mouse and
Human RBCs
Human (50 μL) or mouse (30 μL) RBCs were added to PBS (450 μL
for human RBCs, 270 μL for mouse RBCs) containing 5 mM glucose
and freshly prepared ascorbate, [14C]ascorbate, dehydroascorbic acid,
or [14C]dehydroascorbic acid. RBCs and supernatants were prepared
and analyzed as described previously (Li et al., 2012).
2.6. Inhibition of 3-O-[3H]MG and [14C]DHAUptake intoMouse andHuman
RBCs
2.6.1. Inhibition of 3-O-[3H]MG and [14C]DHA Uptake into Mouse and
Human RBCs by Unlabeled 3-O-MG
Human RBCs 2mL prepared as above were incubated with 20mM
3-O-MG in PBS (ﬁnal volume 20mL) for 20min at 37 °C (See supplemen-
tary methods). After centrifugation at 500 x g for 5 min, the supernatant
was removed and preloaded RBCs placed on ice until use. For competition
between unlabeled and 3-O-[3H]MG, RBC 50 μLwere added to 450 μL PBS
on ice containing 1 μCi/mL 3-O-[3H]MG and one of the following concen-
trations of unlabeled 3-O-MG: 0.005, 1, 2.5, 5, 10, 20, 30 mM. For compe-
tition between unlabeled 3-O-MG, and [14C]DHA, RBC 50 μL were added
to 450 μl PBS on ice containing freshly prepared 5 μM [14C]DHA and one
of the following concentrations of unlabeled 3-O-MG: 0.005, 1, 2.5, 5,
10, 20, 30mM. After incubation on ice for 1min, 1mL ice-cold stop buffer
(10 μM cytochalasin B in PBS) was added, and the mixture centrifuged at
Fig. 1. Hypothesis origin and vitamin C concentrations in RBCs and plasma. A. Hypothesis origins: ﬁndings from centrifugation of mouse whole blood. For ascorbate values, samples were
obtained from 5 Gulo−/−mice supplementedwith ascorbate 1 g/L in drinking water for 12 weeks and 5 Gulo−/−mice not supplemented with ascorbate for 12 weeks, plasma concentra-
tions indicated in thepanel.Gulo−/−mice donotmake ascorbate.When ascorbatewas provided,mice received it via drinkingwater, whichwas changed daily. B.Mouse RBC ascorbate as a
function of plasma ascorbate. 12wildtype (WT)mice were unsupplemented for 14weeks ( ); 10Gulo−/−mice were unsupplemented from 0 to 14weeks ( ); and 5 Gulo−/−micewere
supplementedwith 1 g/L ascorbate in drinkingwater from 0 to 17weeks (●). Each symbol represents a separate blood sample. R= 0.91, p b 0.01. C. HumanRBC ascorbate as a function of
plasma ascorbate in 153 healthy blood donors, ascorbate measured by HPLC with coulometric electrochemical detection (Li et al., 2012). Each samplewasmeasured in triplicate, samples
without error bars indicate SDwas less than symbol size. R= 0.82, p b 0.02. D. Humanmononuclear cell ascorbate (all non-open circle symbols) as a function of plasma ascorbate, ascor-
batemeasured by HPLC. In-patient healthy subjects (6men and 13women)whowere at steady state for vitamin C doses of 30, 60, 100, 200, 400, 1000, and 2500mg in two divided doses
daily underwent apheresis with elutriation of cell-enriched product to obtainmixedmononuclear cells, as described (Levine et al., 1996, 2001). Each symbol represents a different subject.
For each subject, samples were obtained at 1–5 different vitamin C doses at steady state for that dose (Levine et al., 1996, 2001).
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washed twice more at 4 °C. From the resulting RBC pellet, 40 μL were
added to 360 μL ultrapuriﬁedwater and themixture repetitively pipetted
for at least 10 s. The resulting lysatewas transferred to a centrifugal ﬁltra-
tion device (AmiconUltra 0.5ml 10 KUltracell, Millipore) (Li et al., 2012),
and centrifuged at 14,000 x g for 15min at 4 °C. Filtrate 100 μLwas added
to 5mL scintillation ﬂuid followed by scintillation spectrometry analyses.
Mouse RBC experiments were conducted similarly, with the follow-
ing modiﬁcations. For pre-loading RBCs with 3-O-MG, 0.4 mL washed
RBCs were re-suspended in 3.6 mL PBS containing 20 mM 3-O-MG at
37 °C for 20 min, with removal of supernatant and placement on ice
until use. For 3-O-MG competition experiments with 3-O-[3H]MG,
40 μL pre-loaded RBCs were added to 360 μL PBS at 37 °C containing 1
μCi/mL 3-O-[3H]MG with 5 μM or 30 mM unlabeled 3-O-MG. For 3-O-
MG competition experiments with [14C] DHA, 40 μL pre-loaded RBCs
were added to 360 μL PBS at 37 °C containing freshly prepared 5 μM
[14C] DHA with 5 μM or 30 mM unlabeled 3-O-MG. After RBC addition,
mixtures were incubated at 37 °C for 1 min, followed by addition of
ice-cold stop buffer (PBS with 10 μM cytochalasin B), washing, lysis, ﬁl-
tration, and analyses by scintillation spectrometry.2.6.2. Inhibition of 3-O-[3H]MG and [14C]DHA Uptake into Human and
Mouse RBCs by Cytochalasin B
After washed human RBCs 50 μL were re-suspended in 450 μL
PBS with 20 mM 3-O-MG for 20 min at 37 °C as above, 0.5 μL of either
dimethyl formamide alone or containing cytochalasin B was added.Final cytochalasin B concentrationwas 20 μM. After RBCs were incubated
for an additional 15 min at 37 °C, they were pelleted by centrifugation at
50 x g for 5min at 4 °C and 400 μL of supernatantwas removed. The loose
RBC pellet was re-suspended with 500 μL of pre-chilled PBS containing
either 3-O-[3H]MG (5 μM, 1 μCi/mL) or [14C]dehydroascorbic acid
(DHA)(freshly prepared, 5 μM, 0.027 μCi/mL), and incubated for 15, 30,
45 or 60 s on ice. At the end of the incubation time, 1 mL of prechilled
PBS containing 20 mM 3-O-MG and 20 μM cytochalasin B was added,
and RBCs were washed 3 times at 4 °C using this solution. As above, the
ﬁnal pelletwas lysed inwater,ﬁltered using a centrifugalﬁltration device,
and analyzed by scintillation spectrometry.
For mouse RBCs, experiments were conducted as for human RBCs
with the followingmodiﬁcations: time point was oneminute, tempera-
ture was 37 °C.
2.7. Xenopus Laevis Oocyte Transport Assay
cRNAs (complementary RNAs) of humanGLUT 1 ormouseGlut 3were
prepared by in vitro transcription (mMessage mMachine, Ambion).
Xenopus laevis oocytes were isolated and injected with cRNAs as
described (Corpe et al., 2013), see supplementary methods for details.
2.8. Western Blot
For sample preparation, one volume of mouse or human intact red
cells were washed three times with cold PBS before lysis using 4
1738 H. Tu et al. / EBioMedicine 2 (2015) 1735–1750volumes of modiﬁed RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl,
0.1% SDS, 0.25% Na deoxycholate, 2% Triton-X100, 1 mM PMSF, 2uM
leupeptin). Western blot was performed on RBC lysates according
to manufacturer's instructions (Life Technologies, Carlsbad CA), see
supplementary methods for details.
Anti-GLUTs (1–4) antibodies were all polyclonal antibodies. Based
on supplier information, antibodies detected transporters from mice,rats, and humans. For GLUT Western blots of RBC lysates from human
andmice: if no orweak bandswere detected in either species, a positive
control of the species (human/mouse cell lines or isolatedmouse tissue)
was added to determine whether the antibody recognized epitopes
across species, see supplementary methods for details. GLUT 1Western
blots were developed using normal sensitivity substrate (Pierce ECL
Western blot Substrate, Thermo), while other GLUT Western blots
Fig. 2.Osmotic fragility inmouse RBCs as a function of their ascorbate concentrations and underlyingmechanism. A. Osmotic RBC fragility inmouse RBCs as a function of NaCl concentra-
tion. RBC samples were obtained from 5WT unsupplementedmice ( ); 5 Gulo−/−mice without ascorbate for 12 weeks ( ); and 5 Gulo−/−mice supplemented with 1 g/L ascorbate for
12weeks (●); N=5mice per point. The 50% lysis point for each condition (horizontal line) is determined by the vertical line of the same color. Plasma ascorbate concentrations:WTmice,
77.6 μM; Gulo−/−mice, 4.0 μM; Gulo−/−mice supplementedwith 1 g/L ascorbate for 12 weeks 64.8 μM. Statistics (two-tailed T-test) for 50% lysis: WT vs. unsupplementedGulo−/−mice,
p b 0.001; unsupplemented vs supplemented Gulo−/−mice, p b 0.05. Wildtype and supplemented Gulo−/−mice were not statistically different. B. RBC ascorbate as a function of plasma
ascorbate in Gulo−/−mice also tested for RBC osmotic fragility (see Fig. 2C). Five Gulo−/−mice were supplementedwith ascorbate 1 g/L for 17weeks. Ten Gulo−/−mice were deprived of
ascorbate for 0–14weeks, followed by gavage supplementationwith 0.2mg of ascorbate in 100 μL water once at 14 weeks and once at 17weeks. Gavagewas performed tomaintainmice
at low ascorbate values while preventing demise from scurvy (see supplementary methods). N = 5 mice per point. Samples from ascorbate unsupplemented mice indicated by ( );
samples from ascorbate supplemented mice indicated by (●). Individual data points are also included in Fig. 1B. C. RBC osmotic fragility in Gulo−/−mice as a function of RBC ascorbate.
50% RBC lysis (see Fig. 2A) was tested in relation to RBC ascorbate concentration from 5 Gulo−/−mice supplemented with ascorbate 1 g/L for 17 weeks or 10 Gulo−/−mice deprived of
ascorbate for 0–14weeks, and then supplemented by gavage with 0.2 mg of ascorbate in 100 μL water once at 14weeks and once at 17 weeks (see Fig. 2B and supplementary methods).
N = 5mice per point. Star symbols represent 50% lysis of RBCs from Gulo−/−mice unsupplemented (red) or supplemented (black) with ascorbate from Fig. 2A. Samples from ascorbate
unsupplemented mice indicated by ( ); samples from ascorbate supplemented mice indicated by (●). D. Biconcave and total diameters of RBCs from ascorbate supplemented and
unsupplemented Gulo−/− mice. Ascorbate supplemented Gulo−/− mice (N = 6) received ascorbate 1 g/L for 12 weeks, and unsupplemented mice (N = 6) had no ascorbate for
12 weeks (plasma ascorbate concentrations were 66 ± 10 and 1 ± 1 μM respectively, see Fig. 2G). Forty to ﬁfty RBCs in full view orientation using confocal microscopy were randomly
selected from each group for measurement of diameters. ***: p b 0.0001 (t-test). See supplementary Fig. 1B for images. E. β-Spectrin in lysates of mouse RBCs. RBC lysates from ascorbate
supplemented, unsupplemented, and unsupplemented and then resupplemented Gulo−/−male mice were prepared as described in methods. Lysates were analyzed by Western blots
using antibodies to α-spectrin, β-spectrin, ankyrin-1, protein 4.2 and β-actin. β-actin was used as loading control, and triplicates are displayed. Densitometry analyses are below each
band. Left panel: Gulo−/− supplemented vs. unsupplemented mice. Right panel: Gulo−/− supplemented mice vs. gulo−/−mice that were unsupplemented and then resupplemented
for 10 days (labeled Gulo ascorbate recovery). In lower panel, β-spectrin in mouse RBCs was normalized to β-actin for protein band signal intensities, using data from control, depleted
and repleted Gulo−/−mice in two upper panels. Plasma ascorbate concentrations were: 66 ± 10 (supplemented mice, N = 6); 1 ± 1 μM (unsupplemented mice for 12 weeks, N =
6); and 61 ± 9 μM (unsupplemented mice for 12 weeks then resupplemented for 10 days, N = 6). Mice were resupplemented with ascorbate 2 g/L in drinking water to ensure rapid
supplementation. F. Osmotic RBC fragility as a function of NaCl concentration. Gulo−/−mice were deprived of ascorbate for 12 weeks ( ), and the same mice were supplemented with
ascorbate 2 g/L in drinking water for the following 10 days ( ). N = 5 mice per point. The 50% lysis point for each condition (horizontal line) is determined by the vertical line of the
same color. Plasma ascorbate concentrations (see supplementary Fig. 1C): Gulo−/−mice without ascorbate, 1.0 ± 1 μM; Gulo−/−mice supplemented with 2 g/L ascorbate for 10 days,
61 ± 9 μM. For unsupplemented vs. resupplemented RBC 50% lysis: p b 0.005 (two tailed t-test). G. Ascorbate concentrations in plasma and RBCs from Gulo−/−male mice. Mice were
continuously supplemented (N = 5); unsupplemented (N = 8); and unsupplemented then resupplemented (N = 6). Unsupplemented Gulo−/−mice did not receive ascorbate for 12
weeks. Resupplemented mice received ascorbate in drinking water 2 g/L for 10 days. Resupplemented mice had previously not had ascorbate for 12 weeks.
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Pico Chemiluminescent Substrate, Thermo). RBC ghosts were prepared
as described (Steck and Kant, 1974). For mouse RBCs, anti- β 1 spectrinantibody was used to detect β-spectrin, and anti-(α+ β) spectrin anti-
body was used to detect α-spectrin. For human RBCs, anti-(α + β)
spectrin antibody was used to detect β-spectrin and α-spectrin.
1741H. Tu et al. / EBioMedicine 2 (2015) 1735–17502.9. Confocal Microscopy
RBCs were ﬁxed using 0.1% glutaraldehyde, stained with Alexa Fluor
488 phalloidin (5 units/mL), and analyzed by confocal microscopy (Yau
et al., 2012). Confocal laser scanning microscopy analysis was
performed with a Duo-Scan system (LSM 5 LIVE; Carl Zeiss Inc.,
Thornwood, NY) using a 63 × 1.4 NA oil immersion objective. Laser
489 nm line was applied for excitation and emission was collected
with 518 nm ﬁlter. Images were acquired using ZEN 2007 software
(Carl Zeiss, Inc.). Whole cell and biconcave area diameters were
determined by drawing a horizontal line through the center of each
target RBC and calculating the distances between two points where
ﬂuorescent intensities were most different.
2.10. Ascorbic Acid, Dehydroascorbic Acid, and Glucose Analyses
Whole blood glucose was measured by established methods, see
supplementarymethods for details. Brieﬂy, mouse whole blood glucose
measurements were based on conversion of glucose to gluconolactone
(Accu Chek, Roche Diagnostics), and humans samples were measured
by the hexokinase method (Sacks, 2008). Values between methods
used for mouse and human samples are within 10% (Freckmann et al.,
2012). Ascorbic acid and dehydroascorbic acid were measured by
HPLC (high performance liquid chromatography) as described (Li
et al., 2012). RBC intracellular water space was 70% of packed RBC
volume (Kageyama et al., 1989; Mendiratta et al., 1998). Although RBC
volume differs from mice to humans, mice have similar intracellular
water space (Tanabe et al., 1986).White blood cell volumes, determined
as previously described, are 0.25 μL/106 mixed mononuclear cells
(Bergsten et al., 1990).
2.11. Calculations
Data displayed are mean ± S.D. unless otherwise indicated. Num-
bers of patients or mice are indicated in legends. Otherwise, each data
point represents N of at least 3 replicates unless noted differently in ﬁg-
ure legends. Points lacking error bars indicate S.D. was less than symbol
size. Comparisons between 3 or more groups utilized 1-way ANOVA
followed by Tukey's multiple comparison test (Graphpad Prism version
5.01; SigmaPlot version 13). Two groups were compared using, 2-tailed
Student's t test (Excel 2010). p ≤ 0.05 or less was considered signiﬁcant.
Signiﬁcance versus respective control was indicated as follows: *:
p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.005; ****: p b 0.001.
3. Results
3.1. Hypothesis Origin and Relevant Vitamin C Concentrations in Mice and
Humans
The original clue linking ascorbate, diabetes and RBCs came fromun-
expected observations of whole blood obtained from mice (Gulo−/−)
unable to synthesize vitamin C. When whole blood was centrifuged,
samples from unsupplemented mice had visible hemolysis (Fig. 1A).
With slower centrifugation for longer times to prevent hemolysis,Fig. 3.Dehydroascorbic acid and ascorbic acid transport into human andmouse RBCs as a functio
ﬁgure contains four panels. For each grouped ﬁgure: in the left upper panel, RBC ascorbate con
in the right upper panel, RBC ascorbate concentration is shown after incubation with the sam
concentrations: dehydroascorbic acid added on the left lower side, ascorbic acid added on the
human or mouse, and from each human or mouse three or more independent samples were
sides indicate sample analyses by HPLC, with no reducing agent added. For color symbols: gree
during incubation; red symbols ( , ) indicate analyses by scintillation spectrometry, without r
with reducing agent (500 μMTCEP) present during incubation. The concentration of dehydroasc
panel. Additional experiments with concentration of 5 μM is shown in supplementary ﬁgures. F
with 5mMglucose. For mouse RBC experiments, 30 μL RBCswere incubated in 0.3mL total volu
ﬁgures because animals/human often do not have the same initial values, and some data repres
methods and supplementary Fig. 3 legend for other details.plasma ascorbate concentrations could be determined. Ascorbate values
for supplemented Gulo−/−micewere ~74 μM, and for unsupplemented
Gulo−/−mice were ~4 μM. Hemolysis only in samples with low plasma
ascorbate concentrations implicated low vitamin C within RBCs as a
cause. To explore this possibility, we directlymeasuredmouse RBC vita-
min C concentrations, and when compared to plasma concentrations
from the same whole blood samples, a linear relationship was found
(R = 0.91, p b 0.01) (Fig. 1B).
To learnwhethermouse vitamin C datawere relevant to humans, we
measured human plasma and RBC ascorbate concentrations (Fig. 1C). In
whole blood from N150 randomhealthy humans, RBC ascorbate concen-
tration was at or below the associated plasma concentration, with a lin-
ear relationship between both compartments (R = 0.82, p b 0.02). In
N10% of subjects, RBC ascorbate valueswere b20 μM, in the early vitamin
C deﬁciency range (Levine et al., 1996, 2001). The concentrations in RBCs
were then compared to another human circulating cell type,mononucle-
ar cells (Fig. 1D). In contrast to RBCs (Fig. 1C), mononuclear cells had
ascorbate concentrations that were N30-fold higher than concurrent
plasma concentrations (Fig. 1D). Mononuclear cell data are consistent
with other cell-types (Levine et al., 1996, 2001).
3.2. Osmotic Fragility in Mouse RBCs in Relation to Ascorbate Concentrations
and Underlying Mechanism
Based on Fig. 1, low RBC vitamin C concentrations were clinically
plausible. Next stepswere to investigate RBC fragility in relation to plas-
ma and RBC vitamin C concentrations. Because low ascorbate levels are
not easily obtainable in humans (Levine et al., 1996, 2001), we studied
Gulo−/−mice (Maeda et al., 2000). We predicted that plasma and RBC
ascorbate concentrations in Gulo−/−micewould be a function of ascor-
bate depletion or supplementation, and it would be possible to have an-
imals with low or high values. Wildtype (WT) mice, which synthesize
ascorbate, were used as controls. RBC osmotic fragility was a surrogate
for RBC deformability (Clark et al., 1983). RBCs were obtained from
ascorbate unsupplemented Gulo−/− mice with low plasma ascorbate
concentrations (4 μM). These RBCs were more sensitive to osmotic
lysis compared to supplemented Gulo−/− mice with normal plasma
ascorbate concentrations (64 μM) (p b 0.05 for osmotic lysis) and com-
pared to WT mice, with plasma ascorbate concentrations of 77 μM
(p b 0.001 for osmotic lysis) (Fig. 2A). To further characterize osmotic
fragility, it was necessary to use RBCs whose ascorbate concentrations
varied over a wide range. This was achieved by using Gulo−/− mice
andwithholding ascorbate for as long as 14weeks (Fig. 2B, see Fig. 2 leg-
end for details). The longer Gulo−/−mice remained unsupplemented,
the more plasma and RBC ascorbate values declined (supplementary
Fig. 1A). Osmotic fragility was then tested in relation to these declining
RBC ascorbate values (Fig. 2C). Once RBC valueswere b10 μM, increased
osmotic fragility occurred. These data, as in Fig. 2A, indicate that RBC
fragility is inversely related to RBC ascorbate concentration.
To get clues about osmotic fragility induced by ascorbate deﬁciency,
we examined RBCs from ascorbate repleted and depleted Gulo−/−mice
by confocal microscopy. A decreased surface-to-volume ratio indicates
swelling, and internal diameters of RBCs are an inverse function of
swelling because swelling produces a decreased surface-to- volumen of time. Humans RBCs are in grouped FigureA,mouse RBCs are in Figure B. Each grouped
centration is shown after incubation with one concentration of dehydroascorbic acid; and
e concentration of ascorbic acid. The lower panels are the corresponding extracellular
right lower side. Within each panel, a different symbol represents blood from a different
obtained and analyzed at every time point. All open black and white symbols on both
n symbols ( , ) indicate analyses by HPLC, with reducing agent (500 μM TCEP) present
educing agent added; blue symbols ( , ) indicate analyses by scintillation spectrometry,
orbic acid/ascorbic acidwas 2 μM. For clarity, concentrations and species are shown in each
or human RBC experiments, 50 μL RBCs were incubated in 0.5 mL total volume using PBS
me using PBSwith 5mMglucose. Note that initial concentrations are different in the same
ent scintillation spectrometry results, where initial values should be close to or at zero. See
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be expected to decrease deformability, whichwas observed (Fig. 2D). In-
ternal diameters (biconcave diameters) of RBCs were measured using
confocal microscopy, and compared to controls, ascorbate-deﬁcient
RBCs had signiﬁcantly lower internal diameters and a spherocyte-like
appearance (Fig. 2D, supplementary Fig. 1B). The spherocyte appearance
in these mouse RBCs was similar to RBCs from humans withmild hered-
itary spherocytosis, one of the few clinical disorders in which RBCs have
increased osmotic sensitivity. Given the similarities in RBC appearance,
and because human hereditary spherocytosis may be due to defects
in spectrins or ankyrin or both, we used RBCs from Gulo−/− mice to
quantitate these proteins byWestern blot. Gulo−/−mice were ascorbate
supplemented, ascorbate depleted, or ascorbate depleted followed by
re-supplementation. Ankyrin-1 and α-spectrin were unchanged, but
β-spectrin was signiﬁcantly less in RBCs from depleted Gulo−/− male
mice compared to controls (Fig. 2E left side). Depleted Gulo−/− male
mice were repleted with ascorbate for 10 days, and RBCs were re-
studied by Western blot (Fig. 2E right side); osmotic sensitivity
(Fig. 2F); and confocal microscopy (supplementary Fig. 1C). β-
Spectrin in RBCs from depleted then re-supplemented Gulo−/−
mice was similar to β-spectrin in RBCs from continuously supple-
mented Gulo−/− mice (Fig. 2E right side). Western blot ﬁndings for
β-spectrin are summarized in Fig. 2E (lower panel). Osmotic fragility
measurements indicated that compared to controls, ascorbate de-
pleted mice had increased fragility, which was reversed with ascor-
bate supplementation (Fig. 2F). RBC appearance in depleted then
re-supplemented Gulo−/−mice was indistinguishable from controls
(supplementary Fig. 1C). Ascorbate values in plasma and RBCs conﬁrm
supplementation, depletion, and repletion (Fig. 2G). Other than de-
scribed above, RBCs from ascorbate supplemented and deﬁcient male
mice had indistinguishable hematologic parameters (supplementary
Fig. 1D). Using female Gulo−/− mice, we evaluated ankyrin-1 and β-
spectrin in ascorbate supplemented and unsupplemented mice; and
in ascorbate depleted mice that were then re-supplemented for 3 days
(supplementary Fig. 1E-G). Consistent with the ﬁndings using RBCs
frommaleGulo−/−mice, the data showed that onlyβ-spectrin declined,
that the decline reversed within as short a time as 3 days, and that
ascorbate depletion and repletion values in plasma and RBCs were as
predicted. Additionally, acute in vitro supplementation of RBCs from
ascorbate deﬁcient Gulo−/− mice did not reverse the decline in β-
spectrin that was a consequence of low RBC ascorbate (supplementary
Fig. 1H).
3.3. Potential Relationship to Diabetes: Dehydroascorbic Acid and Ascorbic
Acid Transport into Human and Mouse RBCs
The potential connection between ascorbate, RBCs, and diabetes is
that the probable species transported into RBCs is oxidized ascorbate,
or dehydroascorbic acid (DHA), which enters via glucose transporters
and then is immediately reduced intracellularly (Hughes and Maton,
1968; Mann and Newton, 1975; Bianchi and Rose, 1986; Mendiratta
et al., 1998). To delineate the transported species in human and
mouse RBCs, we used estimated physiologic plasma concentrations of
DHA, which are 1–5% of ascorbate (Dhariwal et al., 1991; Lykkesfeldt,
2000); physiologic plasma ascorbate concentrations (Levine et al.,
1996, 2001); freshly synthesized DHA (Rumsey et al., 1997; Corpe
et al., 2013); and a recently developed assay for RBC ascorbate (Li
et al., 2012). Extracellular DHA as substrate was measured to verify its
presence (see Fig. 3 and supplementary Fig. 2). In human RBCs, DHA
at 2 μMwas avidly transported, such that within 2 min nearly all DHA
moles in media were translocated into RBCs and reduced to ascorbate
(Fig. 3A, supplementary Fig. 3 legend). No ascorbate was transported
under the same conditions (Fig. 3A). Using DHA and ascorbate concen-
trations of 5 μM (supplementary Fig. 3A,) and human RBCs, similar
ﬁndings were obtained: only DHA was transported. Mouse RBCs also
transported only DHA and not ascorbate, but transport rates were10–20 fold lower compared to human RBCs (Fig. 3B; supplementary
Fig. 3B). Only ascorbate was found in RBCs (Li et al., 2012) (supplemen-
tary Fig. 4A,B).
3.4. Glucose Inhibition of DHA Uptake into RBCs in vitro, GLUT Transporters
Expressed, and Glucose Effects on RBC Ascorbate Concentrations and
Osmotic Fragility in vivo
Since DHA is exclusively transported, and the likely transporter is a
facilitated glucose transporter (GLUT 1, Glut 3) (Vera et al., 1993;
Rumsey et al., 1997; Corpe et al., 2013), we investigated DHA transport
inhibition by the non-metabolized analog 3-O-methylglucose, using
human RBCs. As essential control, [3H]3-O-methylglucose 5 μM uptake
was inhibited by increasing concentrations of unlabeled 3-O-
methylglucose 1–30 mM (Fig. 4A; supplementary Fig. 5A-E). Under
the same conditions, 5 μM [14C]DHA uptake was inhibited by
1–30 mM 3-O-methylglucose in a matching pattern (Fig. 4B). DHA
was fully reduced to ascorbate under these experimental conditions
(supplementary Fig. 6). To account for transactivation and to maximize
transport, RBCs were pre-loaded with 3-O-methylglucose (Stein, 1986;
Carruthers and Naftalin, 2009; Carruthers et al., 2009; Sage and
Carruthers, 2014). The glucose transporter inhibitor, cytochalasin B,
inhibited uptake of 3-O-methylglucose and DHA nearly identically in
human RBCs (Fig. 4C,D). With mouse RBCs, 30 mM unlabeled 3-O-
methylglucose inhibited [3H]3-O-methylglucose and DHA uptake,
although when compared to human RBCs, inhibition of DHA
uptake by 3-O-MG was less robust (Fig. 4E,F). Similar ﬁndings in
mouse RBCs were obtained with cytochalasin B as an inhibitor of
[3H]3-O-methylglucose and DHA uptake: when compared to human
RBCS, inhibition of DHA uptake by cytochalasin B was less robust
(Fig. 4G,H). Based on Fig. 4, human RBCs transported DHA and 3-O-
MG similarly, while mouse RBCs had a higher rate of 3-O-MG transport
than DHA. Slower transport of DHA inmouse RBCs compared to human
RBCs is consistent with the data in Fig. 3.
Because transport of DHA and its inhibitionwere less robust inmouse
RBCs in vitro compared to human RBCs in vitro, it was uncertain whether
glucosewould affect RBC ascorbate concentrations inmouse RBCs in vivo.
To investigate, we used the AZIP lipoatrophic diabetes mouse model
(Moitra et al., 1998). Thesemice have stable hyperglycemia that reverses
overnight with fasting. RBC ascorbate and blood glucose, measured in
non-fasted and fasted AZIP and WT littermate-control mice, displayed
an inverse relationship (Fig. 5A). The decrease in RBC ascorbate induced
by hyperglycemia occurred between 100 and 200 mg/dl glucose
(5.5–11.1 mM), a key range in diabetes (American Diabetes Association:
Position Statement, 2014, 2015). To learn whether changes in ascorbate
plasma values could explain the inverse relationship between plasma
glucose and RBC ascorbate, plasma ascorbate values were measured as
controls in all groups (Fig. 5B). The ﬁndings showed that there were no
statistically signiﬁcant changes in plasma ascorbate concentrations in
normal and AZIP mice as a function of plasma glucose concentrations.
Therefore, plasma ascorbate concentrations did not account for the ob-
served relationship between glucose and RBC ascorbate. As a corollary,
we investigated whether ascorbate affected glucose values in ascorbate
supplemented and depleted Gulo−/−mice. The values were not statisti-
cally different: 162 ± 14 mg/dl (9 ± 0.7 mM) vs 168 ± 21 mg/dl
(9.3 ± 1.2 mM), respectively, N = 6 per group.
Because DHA transport rates are 10–20 fold different in mouse and
human RBCs, and given conﬂicting data for transporter activities
(Montel-Hagen et al., 2008b; Sage and Carruthers, 2014), we character-
ized GLUTs in these cells (Fig. 6A-G). Human RBCs expressed GLUT 1
dominantly, with trace expression of GLUTs 2–4, generally consistent
with prior ﬁndings (Concha et al., 1997). Mouse RBCs expressed Gluts
3 and 4 but not Glut 1, even when a high sensitivity method was used
(Fig. 6E). Transporter activity data indicate that GLUTs 1 and 3 are by
far the most robust DHA transporters (Rumsey et al., 1997, 2000;
Corpe et al., 2013). Using Xenopus oocytes, we show here that human
Fig. 4.Glucose Inhibition ofDHAuptake into RBCs in vitro; glucose effects on ascorbate concentrations inRBCs in vivo.A, B. Inhibition of 3-O-[3H]MGand [14C]DHAuptake into humanRBCs
by unlabeled 3-O-MG. After loading with 20mM3-O-MG at 37 °C, human RBCs 10% were washed and incubated on ice for 1min with 0–30mMunlabeled 3-O-MG as indicated andwith
either 5 μM 3-O-[3H]MG as control (A) or 5 μM [14C]DHA (B). Uptake of 3-O-MG and DHA were determined by scintillation spectrometry. C,D. Inhibition of 3-O-[3H]MG and [14C]DHA
uptake into human RBCs by cytochalasin B (CytB). After loadingwith 20mM3-O-MG at 37 °C andwithoutwashing, human RBCs 10%were incubated on ice for 1minwith (■) or without
(●) 20 μM cytochalasin B andwith 5 μM3-O-[3H]MG (C) orwith 5 μM [14C]DHA (D). E,F. Inhibition of DHA uptake intoWTmouse RBCs by 3-O-MG. After loading with 20mM 3-O-MG,
mouse RBCs 10%werewashed and incubated at 37 °C for 1min. For control experiments (E), 5 μM3-O-[3H]MGwas added alone orwith 30mM3-O-MG. For DHA uptake experiments (F),
5 μM[14C]DHAwas added alone orwith 30mM3-O-MG. G,H. Inhibition of DHAuptake intoWTmouse RBCsby cytochalasin B. After loadingwith 20mM3-O-MG,mouse RBCs10%were
washed and incubated at 37 °C for 1min. For control experiments (G), 5 μM3-O-[3H]MGwas added alone or with 20 μM cytochalasin B. For DHA uptake experiments (H), 5 μM [14C]DHA
was added alone or with 20 μM cytochalasin B.
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ered together, the data suggest that GLUT 1 is the dominant DHA trans-
porter in human RBCs,whilemouse RBCs utilizeGlut 3, and perhapsGlut
4. Although mouse Glut 3 and human GLUT 1 had similar transportcharacteristics, there was substantially less Glut 3 in mouse RBCs
compared to GLUT 1 in human RBCs (Fig. 6A, C). These ﬁndings are con-
sistent with slower DHA transport in mouse RBCs compared to human
RBCs (see Figs. 3 and 4).
Fig. 5. RBC and plasma ascorbate in mice in relation to glycemia. A. RBC ascorbate as a
function of blood glucose in fed and fasted control ( , ) and fed and fasted diabetic
AZIP mice ( , ). AZIP mice and control littermates were fed chow ad libitum until 16 h
before sacriﬁce. Blood was withdrawn from mice that were fed or fasted 16 h and RBC
ascorbate measured by HPLC. AZIP mice were tested together with littermate controls.
B. Ascorbate plasma concentrations as a function of blood glucose in fed ( ) or fasted
AZIP ( ) mice and fed ( ) or fasted ( ) WT controls. Control and AZIP mice synthesize
ascorbate and do not have an intake requirement for it. Therewas no signiﬁcant difference
between plasma ascorbate values in fastedAZIPmice compared to fastedWTcontrolmice.
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mice and humans, we characterized human RBCs from healthy and
diabetic subjects with respect to ascorbate, osmotic fragility, and β-
spectrin. Ascorbate in RBCs from these subjects was inversely correlated
with fasting glucose (Fig. 7A, supplementary Fig. 7); and osmotic fragil-
ity and severity of diabetes (Fig. 7B). For osmotic fragility, p b 0.05 for
healthy subjects vs. poorly controlled diabetic subjects (hemoglobin
A1C N 7.8). The clinical data describing osmotic fragility in relation to
ascorbate concentration are consistent with mouse ﬁndings (Fig. 2).
Similarly, the clinical data indicating that hyperglycemia is associated
with lower RBC ascorbate concentrations are consistent with mouse
ﬁndings (Fig. 5). Compared to healthy subjects, β-spectrin progressively
declined in subjects with mild and poorly controlled diabetes, while
α-spectrin was unchanged (Fig. 7C, D, E). RBC ascorbate values areshown for these subject groups in Fig. 7E. A linear relationship existed
between plasma and RBC ascorbate with hyperglycemia as well as
with euglycemia (supplementary Fig. 7). With data displayed in this
fashion, it was recapitulated that RBC ascorbate was signiﬁcantly
lower with hyperglycemia compared to euglycemia (supplementary
Fig. 7). How hyperglycemia dynamically affects RBC ascorbate will be
best determined in the same diabetic patients with and without hyper-
glycemia in future clinical experiments.
4. Discussion
The data presented here provide original links between red blood
cell osmotic fragility, vitamin C, and diabetes. Hemolysis was observed
when whole blood was centrifuged from mice with low vitamin C
plasma and RBC concentrations. Similar low vitamin C concentrations
were found in some human subjects from random sampling, and were
consistently produced in mice unable to synthesize vitamin C. Mouse
RBC hemolysis induced by low RBC ascorbate concentrations was
quantitated by osmotic fragility, and reversed whenmicewere repleted
with vitamin C.Mouse RBCswith increased fragility induced by lowRBC
ascorbate were spherocyte-like, with decreased β-spectrin. With
repletion of RBC ascorbate, osmotic fragility and spherocyte appearance
reversed, and β-spectrin was restored. Entry of vitamin C into RBCs was
only via the oxidized form dehydroascorbic acid: ascorbic acid itself was
not transported. Because dehydroascorbic acid and glucose have similar
afﬁnities for facilitated glucose transporters in vitro, our ﬁndings
suggested an innovative connection between dehydroascorbic acid
and diabetes. The putative link was strengthened by experiments
using mouse and human RBCs. Advantages of studies here with
dehydroascorbic acid are that dehydroascorbic acid was synthesized
de novo and its disappearance accounted for. Dehydroascorbic acid
transport, performed for the ﬁrst time approximating physiologic con-
centrations, was progressively inhibited by glucose concentrations
found in diabetes (Fig. 4A and B). Glucose concentrations in vivo, from
diabetic mice and WT controls, were inversely associated with RBC
ascorbate concentrations. Despite differences in GLUT identities in
mouse versus human RBCs, human RBC ascorbate concentrations
were again inversely related to plasmaglucose, osmotic fragility, and se-
verity of diabetes. β-spectrin progressively declined in RBCs as diabetes
worsened.
Considered together, these unique ﬁndings support several parts of
an original overarching hypothesis, famine from feast (Fig. 8), and
provide innovative mechanism links between vitamin C and diabetes.
In essence, diabetes pathophysiologymight produce ascorbate deﬁcien-
cy in RBCs, with potential vascular pathophysiologic consequences. In-
creased RBC rigidity from low ascorbate would cause microvascular, or
local, hypoxia by slowing RBC capillary ﬂow, thereby decreasing oxygen
delivery per unit time. The exciting therapeutic aspect is that local deﬁ-
ciency might be reversible with oral ascorbic acid or dehydroascorbic
acid or both, or intravenous ascorbic acid (Lamas et al., 2013).
In both mice and humans, data indicated that ascorbate concentra-
tions in RBCs were inversely related to hyperglycemia. Competition
in vivo between DHA and glucose is an attractive explanation, but
there are multiple paths that could lead to low RBC ascorbate in
diabetes. For RBCs, diabetes in humans could result in: downregulation
of GLUT1 transporter expression; change in GLUT transporter type
expressed; reduced avidity of GLUT 1 transporters for DHA, i.e. from
oxidative damage (Nishikawa et al., 2000; Yu et al., 2006; Wang et al.,
2012); competition between DHA and elevated glucose concentrations;
accelerated ascorbate utilization coupled to sorbitol formation
within RBCs or exogenous oxidant generation from hyperglycemia
(Nishikawa et al., 2000; Yu et al., 2006; Wang et al., 2012); or altered
vitamin C – vitamin E recycling. Beyond RBCs, plasma ascorbate may
be lower in diabetes due to: less ascorbate intake; decreased ascorbate
intestinal absorption; increased glomerular ﬁltration rate (GFR) or
SVCT1 impairment leading to diminished reabsorption; or increased
Fig. 6. GLUTs in mouse and human RBCs and relevant transport activities. A-F. GLUTs in mouse and human RBCs as determined byWestern blot. For GLUT 1 analyses, 2.5 μL of human or
mouse RBC lysate (RBC 5% v/v) and 20 μg of NIH/3 T3 cell lysate were analyzed. Formouse Glut 1 and Glut 2, 3 and 4 analyses: 10 μL of lysate were analyzed from RBCs (RBC 20% v/v), cells
(NIH/3 T3, Caco-2, U87-MG or MCF-7) or tissues (mouse intestine, brain or skeletal muscle). β-actin was used as loading control in each blot, andα/β spectrin were used to indicate RBC
membrane separation. RBC ghosts were prepared as described (Steck and Kant, 1974). G. DHA uptake in injected Xenopus laevis oocytes. Mouse Glut 3 and human GLUT 1 cRNAs were
injected and expressed in Xenopus laevis oocytes, as described (Rumsey et al., 1997). cRNA concentrations were 1 ng/nL. Sham-injected oocytes were injected with 36.8 nL of water.
Each point is mean value of 10 oocytes ± S.D.
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concentrations were lower, less dehydroascorbic acid would then be
available for RBC entry.Anemia is common in diabetes, with multiple causes (Thomas et al.,
2003, 2006; Craig et al., 2005). Low RBC ascorbate might contribute to
anemia, possibly via low grade chronic hemolysis produced by RBC
1746 H. Tu et al. / EBioMedicine 2 (2015) 1735–1750rigidity. Future studies of diabetic subjects will include measurement of
cell-free hemoglobin and reticulocyte counts in relation to ascorbate.
Future studies will also address whether increased RBC osmotic fragility
caused by low ascorbate has consequences to hemoglobin function.
Consistentwith the famine from feast hypothesis (Fig. 8), it has been
reported that low vitamin C plasma concentrations occur in diabetes
(Will and Byers, 1996; Chen et al., 2006). However, prior associations
between vitamin C and diabetes did not account mechanistically for
vascular complications, other than by generalized oxidative damage.
Except for the dataset presented here, there has been no recognition
that humanswith diabetes have lower than expected vitamin C concen-
trations in their RBCs. Unfortunately, most prior existing datasets for
plasma vitamin C concentrations in diabetic subjects are confounded
by assay artifacts; by prior inabilities to measure RBC ascorbate; andFig. 7. RBC ascorbate and β-spectrin in healthy and diabetic humans. A. Human RBC ascorbate
B. Osmotic fragility in human RBCs as a function of RBC ascorbate concentrations. Symbols as fo
A1C (HgbA1C) 5.7–7.7; ( ), diabetic subjects hemoglobin A1C 7.8–10.6. Statistics for the line de
diabetic subjects were statistically signiﬁcant, p b 0.05. C, D, E. HumanRBCα-spectrin,β-spectri
poorly controlled diabetes (13). Normalized values are in D and subject proﬁles in E. Subjectsby inabilities to measure dehydroascorbic acid directly in plasma or
RBCs (Will and Byers, 1996; Li et al., 2012; Dhariwal et al., 1991;
Lykkesfeldt, 2000). Surprisingly, modern hematology textbooks do not
even describe that there is vitamin C in RBCs (Kaushansky et al., 2010;
Greer et al., 2013). To our knowledge, the data here displaying RBC vs
plasma vitamin C concentrations are the most comprehensive available
to date in healthy and diabetic humans.
Previous investigators found no link between dehydroascorbic acid
transport and glucose in mouse and human RBCs (Montel-Hagen
et al., 2008a), but the ﬁndings may have been due to use of radiolabel
without any direct ascorbatemeasurements; dehydroascorbic acid deg-
radation (Rumsey et al., 1997); ﬂawed kinetics assumptions (Rumsey
et al., 1997; Carruthers and Naftalin, 2009); metabolism of glucose
and the analog 2-deoxyglucose (Carruthers et al., 2009); and lack ofconcentrations as a function of plasma glucose concentrations. N = 39 and R =−0.46.
llows: ( ), healthy subjects hemoglobin A1C 4.5–5.6; ( ), diabetic subjects hemoglobin
scribing all data: N=42 andR=−0.41. Differences between ( ) healthy subjects vs ( )
n, andβ-actin in healthy subjects (14); subjects withmild diabetes (13); and subjects with
were randomly selected based on hemoglobin A1C and sample availability.
Fig. 7 (continued).
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ﬁndings on human RBCs, high co-expression of GLUT 1 with stomatin
was interpreted to enhanceDHA transport but negativelymodulate glu-
cose uptake speciﬁcally in human RBCs (Montel-Hagen et al., 2008b).
Recent data using RBCs and inside out vesicles do not support a role
for a stomatin-regulated pool of GLUT 1 that preferentially transports
DHA rather than glucose. Instead, DHA and glucose were transported
similarly by GLUT 1 (Rumsey et al., 1997; Sage and Carruthers, 2014).
The presence of Glut 4 in mouse RBCs was previously reported
(Montel-Hagen et al., 2008b), and conﬁrmed in the results here. While
Glut-dependent DHA uptake was concluded to be absent from matureFig. 8. Famine From Fmurine RBCs (Montel-Hagen et al., 2008b), the ﬁndings in the present
manuscript suggest this conclusion is incorrect.
In the current experiments we have not assessed dehydroascorbic
acid transport activity of all 14 identiﬁed GLUTs (Mueckler and
Thorens, 2013). In previous experiments, Xenopus oocytes were
microinjectedwith cRNAs for GLUTs 1–12 to assess DHA transport activ-
ity. GLUTs 1 and 3 were at least 10 fold more active than other trans-
porters (Rumsey et al., 1997, 2000; Corpe et al., 2013). Data here are
consistent with these reports. There are no data available describing
DHA transport byGLUTs 13 and 14. GLUT 13 is expressed predominantly
in brain, and transports myo-inositol but not glucose. Although GLUT 14east Hypothesis.
1748 H. Tu et al. / EBioMedicine 2 (2015) 1735–1750may have arisen as a gene duplication of GLUT 3, there is no rodent
homolog, andGLUT 14 is expressedmainly in testis. Relying on identities
of GLUTs in human RBCs, GLUT transport activity for DHA, and known
distribution of GLUTs 1–14, we and others conclude that in human
RBCs DHA is transported by GLUT 1 (Montel-Hagen et al., 2008b; Sage
and Carruthers, 2014). Based on similar reasons, we conclude that
mouse RBCs utilize Glut 3 and Glut 4 for DHA transport, but it is unclear
which transporter predominates.
DHA uptake is unlikely to be due to simple diffusion for several
reasons (see Figs. 4 and 6). Unlabeled 3-O-methylglucose inhibited
[3H]3-O-methylglucose uptake and [14C]DHA uptake similarly. Likewise,
cytochalasin B inhibited [14C]DHA uptake and [3H]3-O-methylglucose
uptake in a comparable manner. In Xenopus oocytes, DHA transport
occurred only when GLUTs were injected. There was no uptake with
sham injection. Together, these data support the conclusion that DHA
is transported on glucose transporters. While DHA diffusion cannot be
excluded in mammalian cells, glucose as a similar molecule requires a
membrane transporter and is transported approximately 104 faster
than diffusion (Elbrink and Bihler, 1975; Mueckler et al., 1985).
We show here that RBC β-spectrin decreased when RBC ascorbate
concentrations were low. With ascorbate repletion, decreased β-
spectrin was restored over as short a time as three days. The average
life span of mouse RBCs is ~40 days (Van Putten, 1958). Thus, β-
spectrin recovery is not due to appearance of new RBCs. We speculate
that changes in β-spectrin may be due to reversible oxidative modiﬁca-
tion that is speciﬁc for ascorbate as an electron donor in RBCs. Although
the full β-spectrin crystal structure is not available, no disulﬁde bonds
were detected in the available crystal structure, suggesting that poten-
tial oxidative modiﬁcation(s) occur at other sites (Ipsaro et al., 2010).
Future experiments will explore these possibilities. Hemoglobin and
spectrin can form complexes that may be facilitated by oxidation. In
one report, complexes formed upon hydrogen peroxide treatment
in vitro (Snyder et al., 1985), but only 0–5.9% of spectrin-hemoglobin
was cross-linked by treating with 45–810 μM H2O2. In another report,
there were only trace amounts of a spectrin-hemoglobin complex
which was detected on Western blot using antibody against hemoglo-
bin (Fortier et al., 1988). In our studies, we did not observe any shifted
spectrin bands using either antibody against both α and β spectrins or
speciﬁc β-spectrin antibody, suggesting that a spectrin-hemoglobin
complex is below detection limits. The existence of other ascorbate-
speciﬁc effects is a reasonable explanation of the decreased β-spectrin
levels that we observed in ascorbate depleted Gulo−/−mice and poorly
controlled diabetic subjects.
Experiments here with ascorbate inmouse RBCs provide original in-
sights coupling RBC fragility to low ascorbate concentrations. Notably,
humans have an essential requirement for ascorbate; human RBCs
have far more avidity than mouse RBCs for DHA; and human and
mouse RBCs have distinctly different GLUT transporter expression.
These species differences matter, and therefore human rather than
rodent experimentation is now the way forward. Clear clinical research
possibilities exist to study RBCs in humans with diabetes in relation
to ascorbate. Many possibilities are described above. Additional experi-
mental goals in humans are to characterize RBC ascorbate concentra-
tions dynamically in humans with diabetes, as a function of glycemia
in each subject. To do so, diabetic subjects with low ascorbate can be
hospitalized; their RBC deformability parameters can be measured
before and during controlled hyperglycemia; after discharge, these
subjects can be supplemented with ascorbate to increase their RBC
ascorbate concentrations; post supplementation, subjects can be re-
hospitalized to againmeasure RBC properties with controlled hypergly-
cemia. Only after RBC ascorbate concentrations are characterized
dynamically in diabetic subjects can longer term goals be approached.
These include determination of oxygen delivery to a relevant appropri-
ate microvascular circulation, and/or clinical outcomes (i.e. progression
of retinopathy) as a function of RBC ascorbate concentrations. Although
it will take time to address unknowns through clinical experimentation,the experimental outcomes have the possibility to substantially impact
clinical practice, and initial studies have begun (NCT02107976 and
NCT00071526, clinical trials.gov).
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